Drugs / Abediterol
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT04199598 | Jan → Apr 2020 | chronic obstructive pulmonary disease | AstraZeneca | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03273127 | Sep → Nov 2017 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02967159 | Nov 2016 → Apr 2017 | asthma, chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02777827 | Jun → Nov 2016 | asthma | AstraZeneca | Completed | Met primary |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT01425801 | Aug 2011 → Feb 2012 | asthma | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT01425814 | Aug 2011 → Mar 2012 | chronic obstructive pulmonary disease | AstraZeneca | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2009-02-23 | Almirall, S.A. | Results Encouraging results support further development of Almirall's almirall.com ↗
A phase II multi-dose study shows fast-acting and long-lasting efficacy of LAS100977, Almirall's novel once-daily inhaled beta2 agonist (LABA), for the treatment of bronchoconstriction in asthmatic patients. |
| 2008-12-10 | Almirall, S.A. | Results Promising results with Almirall's once daily long acting beta agonist (LABA) expected to lead to a development and commercialization partnership in 2009 almirall.com ↗
The pharmaceutical company Almirall successfully completed a phase II study demonstrating superior bronchodilation to twice daily salmeterol and 24-hour efficacy from a single administration of LAS100977, in stable asthmatic patients. |
| 2008-04-22 | Almirall, S.A. | Results Almirall announces promising results with a new compound for asthma and COPD almirall.com ↗
The compound LAS100977 has successfully completed a single dose phase IIa study demonstrating 24 hour efficacy. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-05-11 | Almirall, S.A. | Almirall and Forest to present data from studies of Eklira® (aclidinium bromide) in Chronic Obstructive Pulmonary Disease (COPD) and LAS100977 in asthma almirall.com ↗ |
| 2009-12-17 | Almirall, S.A. | Almirall and Forest Laboratories to expand respiratory collaboration with LAS100977 almirall.com ↗ |
| 2009-02-23 | Almirall, S.A. | Encouraging results support further development of Almirall's almirall.com ↗ |
| 2008-12-10 | Almirall, S.A. | Promising results with Almirall's once daily long acting beta agonist (LABA) expected to lead to a development and commercialization partnership in 2009 almirall.com ↗ |
| 2008-04-22 | Almirall, S.A. | Almirall announces promising results with a new compound for asthma and COPD almirall.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | abediterol | “BACKGROUND: Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination...” PMID 27439370 ↗ Jul 20165“A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma” PMID 25398689 ↗ Nov 2014 |
| Known as | AZD0548 | “Abediterol (AZD0548) is a potential for once daily treatment of asthma and chronic obstructive pulmonary disease (COPD) in fixed dose combination (FDC) with an inhaled...” NCT02777827 ↗ |
| Known as | LAS100977 | “A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma” PMID 25398689 ↗ Nov 2014 |
| Action | Activate | “Abediterol is a novel and selective β2 adrenergic receptor agonist” NCT02967159 ↗1“Beta-2 adrenergic receptor agonist” CHEMBL3039530 ↗ |
| Modality | Small molecule | — CHEMBL3039530 ↗ |
| Route | Inhaled | “Dry powder inhalation” NCT01425801 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL3039530 ↗ |